Drugs / Evacetrapib
Trials 26
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 120 trials | ||||||
| Phase 1 | NCT02497391 | Jul → Nov 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02365558 | Jan → Apr 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02271425 | Oct → Nov 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02226653 | Sep 2014 → Apr 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02156492 | Jun → Dec 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02161731 | Jun → Sep 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02168803 | May 2014 → Dec 2015 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01958489 | Oct 2013 → Jan 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01897493 | Jul → Sep 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01903434 | Jul → Nov 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01908582 | Jul → Sep 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01825876 | Apr → Jun 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01825889 | Apr → Oct 2013 | cardiovascular disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01836185 | Apr → Oct 2013 | liver disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01810432 | Mar → Jun 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01736254 | Dec 2012 → Feb 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01746732 | Dec 2012 → May 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01537887 | Feb → Jun 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01450098 | Oct → Dec 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01448824 | Oct 2011 → Feb 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials · 2 met primary | ||||||
| Phase 2 | NCT01375075 | Jun 2011 → Mar 2012 | hyperlipidemia | Eli Lilly and Company | Completed | Met primary |
| Phase 2 | NCT01105975 | Apr 2010 → Jun 2011 | hyperlipidemia | Eli Lilly and Company | Completed | Met primary |
| Phase 34 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT02260648 | Jan → Nov 2015 | hyperlipidemia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT02260635 | Nov 2014 → Jul 2015 | hyperlipoproteinemia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT02227784 | Oct 2014 → Dec 2015 | hyperlipidemia | Eli Lilly and Company | Terminated | Met primary |
| Phase 3 | NCT01687998 | Oct 2012 → Mar 2016 | cardiovascular disorder | Eli Lilly and Company | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-10-12 | Eli Lilly and Company | Results Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease lilly.com ↗
Eli Lilly and Company (NYSE: LLY) and the ACCELERATE study's academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of the investigational medicine evacetrapib, due to insufficient efficacy. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-10-12 | Eli Lilly and Company | Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease lilly.com ↗ |
| 2015-07-27 | Eli Lilly and Company | Lilly Provides Update on Evacetrapib Phase 3 Trial lilly.com ↗ |
| 2015-02-19 | Eli Lilly and Company | Lilly Provides Update on Evacetrapib Phase 3 Trial lilly.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Evacetrapib | “LY2484595 (evacetrapib): 200 milligrams (mg) of LY2484595 administered orally, one time only” NCT01450098 ↗ |
| Known as | LY2484595 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01450098 ↗ |
| Action | Inhibit | “The cholesteryl ester transfer protein inhibitor evacetrapib” PMID 28514624 ↗ May 20171“Cholesteryl ester transfer protein inhibitor” CHEMBL2017179 ↗ |
| Modality | Small molecule | — CHEMBL2017179 ↗ |
| Route | Oral | “Administered orally” NCT01448824 ↗ |
| Target | CETP | “Cholesteryl ester transfer protein inhibitor” CHEMBL2017179 ↗ |